Power3 Medical Files Additional Patents Strengthening Intellectual Property Portfolio

THE WOODLANDS, Texas, Dec. 20, 2004 (PRIMEZONE) -- Texas Power3 Medical Products, Inc. (OTCBB:PWRM) a leading proteomics company, announces the filing of numerous patent applications on screening and diagnostic assay designs using protein biomarkers for the detection and monitoring of a broad range of diseases, including neurodegenerative diseases and breast cancer.

On December 16th, Power3 Medical filed two provisional patent applications involving the discovery and identification of biomarkers for breast cancer using the Company's proprietary proteomic methodologies. The filed patents entitled, 'An Ubiquitin-Related Protein as a Biomarker for Breast Cancer' and 'Decreased Oxidative Stress Protection as a Biomarker for Breast Cancer' mark an important step for the Company in its intellectual property protection strategy.

Additionally, Power3 Medical filed seven provisional patents earlier this month covering specific protein biomarkers and drug targets for neurodegenerative disease. These patent filings are jointly owned by the Company and Baylor College of Medicine.

Dr. Ira L. Goldknopf, the Company's Chief Scientific Officer said, "The filing of these patents is a significant milestone for the Company. We have been able to create effective diagnostic assay designs because the identification of our protein biomarkers is based on definitive differences in patient samples and can be related to clinical disease. This IP can be licensed to pharmaceutical companies, diagnostic test manufacturers, and other biotech companies for the development of commercial applications."

About Power3 Medical Products, Inc.

Power3 Medical Products, www.Power3Medical.com, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.


Contact Data